1
In conclusion, further investigation of etoposide in malignant mesothelioma is not recommended.
2
Seric values have been evaluated in 24 patients receiving high doses of etoposide.
3
Patients in group A did not receive either MTX or etoposide.
4
Six patients had been treated with concurrent cisplatin and etoposide plus chest x-ray.
5
One cell line resistant to etoposide-induced apoptosis failed to show degradation of DNA-PKcs.
6
The clinical course suggested that the combination of etoposide with prednisolone caused this side-effect.
7
All patients received etoposide and carboplatin every 3 weeks for up to six cycles.
8
The relationship between genotype and etoposide disposition differed by race and by prednisone use.
9
Similarly, endogenous PICOT was cleaved in cell death responses induced by staurosporine and etoposide.
10
No responses were seen in 16 assessable patients despite etoposide levels in the cotoxic range.
11
Two different etoposide doses were tested in eight patients.
12
After administration of etoposide, she failed to recover from severe leukopenia and suffered from meningitis.
13
Arsenic enhanced the cytotoxic response to etoposide suggesting an inhibition of DNA repair, unlike uranium.
14
Cells expressing CD44 were significantly resistant to etoposide-induced apoptosis.
15
Interestingly, the interstitial pneumonia resolved promptly with etoposide therapy.
16
Induction was two cycles of cisplatin and etoposide plus concurrent chest RT to 45 Gy.
